These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 7843255

  • 1. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis.
    Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G.
    Eur J Immunol; 1995 Jan; 25(1):6-12. PubMed ID: 7843255
    [Abstract] [Full Text] [Related]

  • 2. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 3. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice.
    Haas C, Ryffel B, Le Hir M.
    J Immunol; 1998 Apr 15; 160(8):3713-8. PubMed ID: 9558072
    [Abstract] [Full Text] [Related]

  • 4. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
    Enghard P, Langnickel D, Riemekasten G.
    Scand J Rheumatol; 2006 Apr 15; 35(3):209-16. PubMed ID: 16766368
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S, Trick D, Kamino K, Matthias T, Kniesch K, Schlegelberger B, Schmidt RE, Witte T.
    Arthritis Rheum; 2005 Nov 15; 52(11):3629-38. PubMed ID: 16255055
    [Abstract] [Full Text] [Related]

  • 6. Sophorae radix reduces autoimmune response in NZB/w F1 systemic lupus erythematosus mouse model.
    Ko E, Lee Y, Park N, Cho C, Yim YN, Kim J, Kim YS, Kim D, Shin MK, Hong MC, Bae H.
    Lupus; 2007 Nov 15; 16(5):335-41. PubMed ID: 17576735
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice.
    Chen M, Aosai F, Norose K, Mun HS, Ishikura H, Hirose S, Piao LX, Fang H, Yano A.
    Int Immunol; 2004 Jul 15; 16(7):937-46. PubMed ID: 15148287
    [Abstract] [Full Text] [Related]

  • 9. Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand.
    Nakajima A, Hirai H, Kayagaki N, Yoshino S, Hirose S, Yagita H, Okumura K.
    J Autoimmun; 2000 Mar 15; 14(2):151-7. PubMed ID: 10677246
    [Abstract] [Full Text] [Related]

  • 10. Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-gamma receptor treatment.
    Schrott LM, Crnic LS.
    Brain Behav Immun; 1998 Jun 15; 12(2):90-106. PubMed ID: 9646935
    [Abstract] [Full Text] [Related]

  • 11. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
    Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY.
    Immunology; 2006 Nov 15; 119(3):296-305. PubMed ID: 17067309
    [Abstract] [Full Text] [Related]

  • 12. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule.
    Nakajima A, Azuma M, Kodera S, Nuriya S, Terashi A, Abe M, Hirose S, Shirai T, Yagita H, Okumura K.
    Eur J Immunol; 1995 Nov 15; 25(11):3060-9. PubMed ID: 7489744
    [Abstract] [Full Text] [Related]

  • 13. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
    Wofsy D, Seaman WE.
    J Immunol; 1987 May 15; 138(10):3247-53. PubMed ID: 3106478
    [Abstract] [Full Text] [Related]

  • 14. Lipopolysaccharide-induced glomerulonephritis develops in the absence of interferon-gamma signaling.
    Haas C, Car B, Ryffel B, Le Hir M.
    Exp Nephrol; 1996 May 15; 4(4):222-30. PubMed ID: 8864725
    [Abstract] [Full Text] [Related]

  • 15. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody.
    Ravirajan CT, Wang Y, Matis LA, Papadaki L, Griffiths MH, Latchman DS, Isenberg DA.
    Rheumatology (Oxford); 2004 Apr 15; 43(4):442-7. PubMed ID: 15024133
    [Abstract] [Full Text] [Related]

  • 16. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: analysis of T-cell lymphokine synthesis.
    Sato MN, Minoprio P, Avrameas S, Ternynck T.
    Immunology; 1995 May 15; 85(1):26-32. PubMed ID: 7635519
    [Abstract] [Full Text] [Related]

  • 17. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.
    Haas C, Ryffel B, Le Hir M.
    J Immunol; 1997 Jun 01; 158(11):5484-91. PubMed ID: 9164971
    [Abstract] [Full Text] [Related]

  • 18. Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice.
    Espejo C, Penkowa M, Sáez-Torres I, Xaus J, Celada A, Montalban X, Martínez-Cáceres EM.
    Exp Neurol; 2001 Dec 01; 172(2):460-8. PubMed ID: 11716570
    [Abstract] [Full Text] [Related]

  • 19. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR.
    J Immunol; 1998 Jul 01; 161(1):494-503. PubMed ID: 9647261
    [Abstract] [Full Text] [Related]

  • 20. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR.
    J Am Soc Nephrol; 2005 Nov 01; 16(11):3264-72. PubMed ID: 16221871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.